Daniel Devine & Co’s iShares Biotechnology ETF IBB Stock Holding History

Daniel Devine & Co’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$3.92M	Hold	35,655	–	–	3.13%	5
2018 Q1	$3.81M	Sell	35,655 -6,930	-16%	-$768K	3.09%	6
2017 Q4	$4.55M	Hold	42,585	–	–	3.29%	6
2017 Q3	$4.74M	Buy	42,585 +2,490	+6%	+$266K	3.62%	5
2017 Q2	$4.14M	Hold	40,095	–	–	3.38%	6
2017 Q1	$3.92M	Sell	40,095 -6,825	-15%	-$653K	3.22%	6
2016 Q4	$4.15M	Sell	46,920 -5,655	-11%	-$515K	2.96%	6
2016 Q3	$5.07M	Hold	52,575	–	–	3.41%	6
2016 Q2	$4.51M	Buy	52,575 +17,010	+48%	+$1.53M	3.08%	6
2016 Q1	$3.09M	Buy	35,565 +270	+0.8%	+$24.1K	2.02%	9
2015 Q4	$3.98M	Sell	35,295 -615	-2%	-$66.8K	2.63%	8
2015 Q3	$3.63M	Buy	+35,910	New	+$4.31M	2.57%	8

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Daniel Devine & Co's IBB Position: Q2 2018 in Review

Daniel Devine & Co held its iShares Biotechnology ETF (IBB) position steady in Q2 2018 at 35,655 shares worth $3.92M. The position accounts for 3.13% of the portfolio, ranked #5.

Daniel Devine & Co first reported a position in IBB in Q3 2015 and has held it in 12 quarters since. The position peaked at $5.07M in Q3 2016. 609 funds tracked by Wall St. Rank hold IBB as of Q2 2018.

Daniel Devine & Co held 35,655 shares of iShares Biotechnology ETF worth $3.92M as of Q2 2018.
Daniel Devine & Co left its iShares Biotechnology ETF share count unchanged in Q2 2018.
iShares Biotechnology ETF made up 3.13% of Daniel Devine & Co's portfolio in Q2 2018, its #5 holding.
Daniel Devine & Co first reported a position in iShares Biotechnology ETF in Q3 2015 and has held it in 12 quarters since.
Daniel Devine & Co's iShares Biotechnology ETF position peaked at $5.07M in Q3 2016.
609 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2018.

Based on Daniel Devine & Co's 13F filing for Q2 2018, filed 18 Jul 2018.